Abstract Allogeneic stem cell transplantation (SCT) is a curative treatment in myelodysplastic syndromes (MDS). We performed a retrospective single center study of all patients with newly diagnosed higher risk (HR) MDS (IPSS-R > 3.5 points) between 2000 and 2023. We identified…
Introduction: Paroxysmal nocturnal haemoglobinuria (PNH) is an uncommon, life-threatening disease, caused by intravascular haemolysis by the complement system
Patients at risk for progression from myeloid precursor states (ICUS, CCUS) to MDS are not well defined. Epidemiologic risk factors, clonal changes for MDS development, and evolution from one MDS state to another (lower- (LR) or higher-risk (HR) disease or leukemia [AML]) are available in the MDS NHS, a prospective cohort enrolled at diverse US sites. Extensive clinical data and biospecimens are collected at baseline and follow-up.
About 25% of patients with myelodysplastic syndromes myelodysplastic syndromes:
Introduction: Myelodysplastic syndromes Myelodysplastic syndromes:
Aside from allogeneic transplantation, the current standard-of-care approach for higher-risk myelodysplastic syndromes
The COMMANDS trial established luspatercept as a first-line treatment for anemia anemia:
To improve the tolerability of posttransplant maintenance and outcomes despite poor-risk disease genetics, we conducted a phase 1 study of venetoclax venetoclax: